OS Therapies Inc (OSTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US68764Y2072
OS Therapies Inc financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -28.71 m USD |
| EBIT | -28.75 m USD |
| Net income | -28.75 m USD |
| Diluted EPS – continuing operations | -0.98 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About OS Therapies Inc
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
More stocks
- ABUNDIA GLOBAL IMPACT GROUP, INC. (AGIG)
- EyePoint, Inc. (EYPT)
- RecensMedical, Inc. (394420.KQ)
- SITE Centers Corp. (SITC)
- Royalty Management Holding Corp (RMCO)
- Nano Labs Ltd (NA)
- Ideal Power Inc. (IPWR)
- U S GLOBAL INVESTORS INC (GROW)
- Wintec Co. Ltd (320000.KQ)
- InfraCom Group AB (INFRA.ST)
- Forward Industries, Inc. (FWDI)
- INTERPACE BIOSCIENCES, INC. (IDXG)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.